Glutatyon eksiklii, isel ve dsal faktrlerden kaynaklanabilir
Burke, L., Cort, M., Cox, G., Crawford, R., Desbrow, B., Farthing, L., Minehan, M., Shaw, N
Molecular & Cellular Oncology, 6 (5), e1627273
Although their basal drug encapsulation efficiency and release behaviors can be dictated by formulating them into distinct sizes and lamellarities (such as small unilamellar, large unilamellar, and multilamellar vesicles), relying solely on this internal skeleton is often insufficient to fully overcome the complex oral delivery barriers ( in vivo circulation time, and achieves active targeting to specific intestinal sites (e.g., small intestine or colon)
Patient self-management: Many patients become adept at recognising early signs of B12 deficiency (such as fatigue or paraesthesia) if injections are delayed
Jenn and I discuss: How natural GLP-1 production can decline with age Why under-fueling is still the primary issue for many athletes Different types and forms of GLP-1 meds Who should (and shouldn't) consider these medications Potential risks of GLP-1 use, including muscle loss, bone density loss, and GI distress Potential benefits to inflammation, autoimmune conditions, gut health, and mood Nutrition and supplement strategies when appetite is lower Dosing and microdosing for therapeutic use, not just weight loss Why some athletes cycle on and off these meds, or may only need them for a short period of time Why Jenn takes most clients off GLP-1s during race training The stigma around GLP-1 use among athletes Jenn's own story: early menopause, a cardiovascular family history, and how a short course changed her running Why solid diet and lifestyle habits must always come first I hope this episode helps you better understand the complexities of GLP-1 medications in endurance athletes, and why there's rarely a simple yes-or-no answer to the questions we explore together
